Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Sep 2025 is 0.54% vs 40.46% in Sep 2024
Consolidate Net Profit
YoY Growth in quarter ended Sep 2025 is 39.00% vs 24.56% in Sep 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Sep 2025 is 34.47% vs 28.70% in Sep 2024
Interest
YoY Growth in quarter ended Sep 2025 is -21.95% vs 95.24% in Sep 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024
Compare Quarterly Results Of Shanghai MicuRx Pharmaceutical Co., Ltd. With
Quarterly - Net Sales
QoQ Growth in quarter ended Sep 2025 is 9.47% vs 1.81% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 0.54% vs 40.46% in Sep 2024
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Sep 2025 is 28.70% vs -25.00% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 39.00% vs 24.56% in Sep 2024
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Sep 2025 is 23.55% vs -27.37% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 34.47% vs 28.70% in Sep 2024
Quarterly - Interest
QoQ Growth in quarter ended Sep 2025 is 0.00% vs 3.23% in Jun 2025
YoY Growth in quarter ended Sep 2025 is -21.95% vs 95.24% in Sep 2024
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024






